Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2

Author:

Van Egeren Debra12ORCID,Stoddard Madison3ORCID,White Laura4ORCID,Hochberg Natasha56,Rogers Michael78,Zetter Bruce78,Joseph-McCarthy Diane9ORCID,Chakravarty Arijit3

Affiliation:

1. Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA

2. New York Genome Center, New York, NY 10013, USA

3. Fractal Therapeutics, Lexington, MA 02420, USA

4. Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA

5. Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA

6. Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA

7. Department of Surgery, Harvard Medical School, Boston, MA 02115, USA

8. Vascular Biology Program, Boston Children’s Hospital, Boston, MA 02115, USA

9. Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA

Abstract

The rapid emergence of immune-evading viral variants of SARS-CoV-2 calls into question the practicality of a vaccine-only public-health strategy for managing the ongoing COVID-19 pandemic. It has been suggested that widespread vaccination is necessary to prevent the emergence of future immune-evading mutants. Here, we examined that proposition using stochastic computational models of viral transmission and mutation. Specifically, we looked at the likelihood of emergence of immune escape variants requiring multiple mutations and the impact of vaccination on this process. Our results suggest that the transmission rate of intermediate SARS-CoV-2 mutants will impact the rate at which novel immune-evading variants appear. While vaccination can lower the rate at which new variants appear, other interventions that reduce transmission can also have the same effect. Crucially, relying solely on widespread and repeated vaccination (vaccinating the entire population multiple times a year) is not sufficient to prevent the emergence of novel immune-evading strains, if transmission rates remain high within the population. Thus, vaccines alone are incapable of slowing the pace of evolution of immune evasion, and vaccinal protection against severe and fatal outcomes for COVID-19 patients is therefore not assured.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference60 articles.

1. Immunological Characteristics Govern the Transition of COVID-19 to Endemicity;Lavine;Science,2021

2. Lavine, J.S., Bjornstad, O.N., Coombs, D., and Antia, R. (2021). Severity of SARS-CoV-2 Reinfections in Second Wave Determines Likelihood of Mild Endemicity. MedRxiv.

3. Phillips, S. (2022, October 04). The New Normal for COVID Calls for a New Narrative. Available online: https://www.scientificamerican.com/article/the-new-normal-for-covid-calls-for-a-new-narrative/.

4. Ghebreyesus, T.A. (2022, October 04). WHO Director-General’s Opening Remarks at the COVID-19 Media Briefing. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-covid-19-media-briefing--17-august-2022.

5. Managing Population Health Risks as We Learn to Live with COVID-19;Trottier;Can. J. Public Health,2022

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3